Indian medtech company Ayati Devices has raised ₹15 crore in a pre-Series A funding round led by Inflexor Ventures, giving the company fresh capital to expand manufacturing and accelerate development of its integrated diabetic-foot and vascular diagnostic platform.
The round represents Ayati’s first institutional investment and comes as the company looks to expand both within India and internationally. The new funding will be used for manufacturing capacity, international regulatory approvals, recruitment and further research and development in AI-enabled diagnostics.
For India’s prosthetics, orthotics and diabetic-foot community, the investment is significant because Ayati is targeting a problem closely linked to lower-limb amputation: identifying neuropathy, vascular disease, abnormal loading and impaired tissue perfusion before they progress to ulceration and limb loss.
From IIT Bombay project to commercial medtech company
Ayati was founded in 2019 by Nishant Kathpal following work through an engineering programme at IIT Bombay that brought clinicians and engineers together to address real healthcare problems.
Kathpal’s involvement with diabetic-foot technology became personal after discovering that three members of his own family had been severely affected by the condition. That experience helped move the project from an academic engineering challenge into a commercial medical-device company.
Today, Ayati describes itself as a foot-health-focused medtech company developing point-of-care technologies across four key areas: neuropathy, blood flow, microcirculation and plantar pressure.
Its broader Ayati Foot Labs concept is designed to bring those assessments together within a connected clinical ecosystem rather than requiring each test to operate as an isolated diagnostic process.
More than 10,000 devices deployed
Ayati says it has now deployed more than 10,000 devices across over 30 countries, although the majority of installations remain in India.
International deployments include countries such as Denmark and Spain, while the company reports regulatory clearances or approvals in markets including India, the United States, Europe, Sri Lanka, Malaysia and the UAE.
That level of deployment is important because diabetic-foot technology can sometimes struggle to move beyond pilot projects or specialist centres.
Ayati’s strategy is instead built around moving screening closer to the patient, including into primary-care centres, diabetes clinics, hospitals and screening programmes.
This could be particularly relevant in India, where patients with diabetes may receive regular blood-glucose monitoring but far less systematic assessment of their feet.
Filling the gap before ulceration
Ayati’s central argument is that diabetic-foot care often becomes specialist-led only after the patient has already developed an ulcer, infection or other serious complication.
The company is trying to intervene earlier.
Its portfolio includes Vibrasense for quantitative vibration-perception testing, Vibrasense+T for assessment of large- and small-fibre nerve function, Vasosense for peripheral arterial disease assessment, Angiocam for tissue-perfusion imaging and the PODIA Trolley, which provides a pay-per-test screening model.
Ayati’s Vibrasense system, for example, measures vibration perception threshold and is designed to provide objective point-of-care screening for large-fibre neuropathy. The device is portable, rechargeable and can generate digital reports for monitoring over time.
The wider Foot Labs ecosystem also incorporates plantar-pressure assessment alongside vascular and neurological testing.
For CPOs and podiatrists, that combination is particularly relevant.
Diabetic-foot risk cannot be understood through a single measurement. Loss of protective sensation, compromised blood flow, altered biomechanics and high plantar pressure can interact to create areas vulnerable to tissue breakdown.
A more integrated assessment may therefore help identify patients requiring footwear modification, insoles, pressure redistribution, closer monitoring or referral before a wound develops.
AI designed to support, not replace, clinicians
A major part of Ayati’s next development phase will involve artificial intelligence.
Kathpal said the company does not intend AI to replace clinical judgement. Instead, it plans to use AI to provide clinicians with additional insights from measurements gathered by its devices.
The longer-term aim is more ambitious.
Ayati wants AI to function as a common intelligence layer connecting nerve function, vascular assessment, plantar biomechanics and circulation data. This could eventually enable the system to provide broader risk stratification rather than simply returning separate results from individual tests.
The company also plans to use accumulated data to help predict ulcer risk and guide personalised follow-up schedules.
If clinically validated, this could be important for large-scale diabetic-foot programmes.
The challenge in India is not only identifying high-risk patients, but also deciding which patients require urgent specialist intervention and which can be managed through scheduled monitoring.
Manufacturing expansion is a major use of funding
A significant proportion of the ₹15 crore investment will go towards increasing manufacturing capacity.
Ayati currently performs integration, assembly, quality control and programming internally while sourcing individual electronic components externally.
Its previous production facility had capacity for approximately 150 devices per month. The company has now moved into a larger facility, although the capacity of the expanded operation has not been disclosed.
The company also plans to increase its workforce substantially. Ayati currently employs 26 people and expects to approximately double that figure in the coming months.
International expansion is planned across Europe, the United States, the Middle East, Southeast Asia, Australia and Latin America.
A growing opportunity for CPOs and podiatrists
For Bharat CPO readers, Ayati’s growth raises an important question about where diabetic-foot care fits within the future scope of the O&P profession.
Prosthetists frequently enter the diabetic-care pathway only after amputation has occurred.
But orthotists, pedorthists, podiatrists and multidisciplinary diabetic-foot teams can potentially intervene much earlier through pressure assessment, footwear, orthoses and risk monitoring.
Technologies capable of identifying neuropathy, vascular compromise and high plantar loading could therefore provide opportunities for O&P clinics to become more involved in limb preservation rather than exclusively post-amputation rehabilitation.
This is particularly relevant because Ayati is deliberately designing its technologies for use outside major specialist hospitals. Its systems are intended for clinics, outreach programmes and primary-care settings as well as larger institutions.
That decentralised approach fits India’s healthcare geography, where access to specialist diabetic-foot centres remains uneven.
India’s foot-health technology ecosystem is becoming more sophisticated
Ayati’s institutional funding round is also another indication that Indian foot-health technology is moving beyond simple standalone screening devices.
The company is trying to build a connected platform spanning nerve function, macrovascular circulation, microcirculation and plantar biomechanics, with AI eventually helping to interpret information across those domains.
For clinicians, the value of such platforms will ultimately depend on clinical evidence, workflow integration and whether the additional data results in better patient decisions and lower rates of ulceration and amputation.
But the direction is important.
India has an enormous diabetes burden, and preventing a diabetic foot ulcer is clinically and economically preferable to treating an infected wound or performing an amputation.
Ayati’s ₹15 crore raise shows that investors increasingly see opportunities not only in treating advanced disease, but in technologies designed to identify risk earlier.
For India’s O&P profession, that should be particularly relevant.
The future of lower-limb care may increasingly begin before the patient becomes an amputee.
- ETEntrepreneur – Ayati Devices raises ₹15 crore pre-Series A funding
- Ayati Devices
- Ayati Foot Labs
- Ayati Vibrasense
- Bharat CPO